Immunomedics CEA-Scan gains unanimous approval recommendation at Feb. 16 panel meeting.
This article was originally published in The Gray Sheet
Executive SummaryIMMUNOMEDICS CEA-SCAN IDENTIFIES LESIONS MISSED BY CT, FDA's Patricia Keegan, MD, branch chief in the Division of Oncology at the Center for Biologics Evaluation and Research, told a Feb. 16 meeting of FDA's Medical Imaging Drugs Advisory Committee. The committee recommended approval of the murine monoclonal antibody fragment-based imaging agent directed against the carcinoembryonic antigen (PLA 91-0209).
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.